Table 3

Overall estimate of incidence of anterior uveitis and CME based on prospective RCT data

Prostaglandin agentNumber at riskUveitis
n (%)
CME
n (%)
Surgical-related CME
n (%)
Latanoprost12 17059 (0.48)17 (0.14)6 (0.05)
Bimatoprost67461 (0.01)00
Tafluprost4605000
Travoprost2830000
Latanoprostene Bunod1391000
Unoprostone118000
ONO 9054932 (2.15)00
Bimatoprost+travoprost81000
Latanoprost+travoprost75002 (2.67)
Latanoprost+tafluprost67000
Latanoprost+unoprostone56000
  • Using prospective data, the incidence of uveitis and CME among PGA users was 62/28 232 (0.22%) and 25/28 232 (0.09%), respectively.

  • Bimatoprost 0.3 mg/mL was used in the patient who developed uveitis.

  • CME, cystoid macular oedema; PGA, prostaglandin analogue; RCT, randomised controlled trial.